Application of a risk analysis method to different technologies for producing a monoclonal antibody employed in hepatitis B vaccine manufacturing.

CB.Hep-1 monoclonal antibody (mAb) is used for a recombinant Hepatitis B vaccine manufacturing, which is included in a worldwide vaccination program against Hepatitis B disease. The use of this mAb as immunoligand has been addressed into one of the most efficient steps of active pharmaceutical ingredient purification process. Regarding this, Quality Risk Management (QRM) provides an excellent framework for the risk management use in pharmaceutical manufacturing and quality decision-making applications. Consequently, this study sought applying a prospective risk analysis methodology Failure Mode Effects Analysis (FMEA) as QRM tool for analyzing different CB.Hep-1 mAb manufacturing technologies. As main conclusions FMEA was successfully used to assess risks associated with potential problems in CB.Hep-1 mAb manufacturing processes. The severity and occurrence of risks analysis evidenced that the percentage of very high severe risks ranged 31.0-38.7% of all risks and the huge majority of risks have a very low occurrence level (61.9-83.3%) in all assessed technologies. Finally, additive Risk Priority Number, was descending ordered as follow: transgenic plants (2636), ascites (2577), transgenic animals (2046) and hollow fiber bioreactors (1654), which also corroborated that in vitro technology, should be the technology of choice for CB.Hep-1 mAb manufacturing in terms of risks and mAb molecule quality.

[1]  N. Lonberg.  Human antibodies from transgenic animals , 2005, Nature Biotechnology.

[2]  C. Hendriksen,et al.  Production of monoclonal antibodies by the ascites method in laboratory animals. , 1998, Research in immunology.

[3]  H. Warzecha.  Biopharmaceuticals from Plants: A Multitude of Options for Posttranslational Modifications , 2008, Biotechnology & genetic engineering reviews.

[4]  R. Valdés,et al.  Comparison of different elution conditions for the immunopurification of recombinant hepatitis B surface antigen. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[5]  I. Wilmut,et al.  Viable offspring derived from fetal and adult mammalian cells , 1997, Nature.

[6]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[7]  C F Hendriksen,et al.  A Call for a European Prohibition of Monoclonal Antibody Production by the Ascites Procedure in Laboratory Animals , 1998, Alternatives to laboratory animals : ATLA.

[8]  M. Wilchek,et al.  The use of cyanogen bromide and other novel cyanylating agents for the activation of polysaccharide resins , 1984 .

[9]  C. Borroto,et al.  Large-scale purification of an antibody directed against hepatitis B surface antigen from transgenic tobacco plants. , 2003, Biochemical and biophysical research communications.

[10]  Clark Aj.  The mammary gland as a bioreactor: expression, processing, and production of recombinant proteins. , 1998 .

[11]  Tatiana Alvarez,et al.  CB.Hep-1 hybridoma growth and antibody production using protein-free medium in a hollow fiber bioreactor , 2001, Cytotechnology.

[12]  M. Pujol,et al.  Using quality risk management in the plantibody HB-01 manufacturing by transgenic tobacco Plants for vaccine production , 2010 .

[13]  Uwe Marx,et al.  Monoclonal Antibody Production , 1997 .

[14]  Huub Schellekens,et al.  Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  R. Palmiter,et al.  Production of transgenic rabbits, sheep and pigs by microinjection , 1985, Nature.

[16]  C. Hendriksen,et al.  In vivo and In vitro production of monoclonal antibodies: Current possibilities and future perspectives , 1998 .

[17]  T. Frank,et al.  Quality Risk Management Principles and Industry Case Studies , 2008 .

[18]  R. Valdés,et al.  Stirrer tank: an appropriate technology to immobilize the CB.Hep-1 monoclonal antibody for immunoaffinity purification. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[19]  I. Wilmut,et al.  Sheep cloned by nuclear transfer from a cultured cell line , 1996, Nature.

[20]  K John Morrow,et al.  Advances in antibody manufacturing using mammalian cells. , 2007, Biotechnology annual review.

[21]  M. Ayala,et al.  Antigen recognition characteristics and comparative performance in immunoaffinity purification of two monoclonal antibodies specific for the hepatitis B virus surface antigen. , 1997, Journal of biotechnology.

[22]  S. Schillberg,et al.  Apoplastic and cytosolic expression of full‐size antibodies and antibody fragments in Nicotiana tabacum , 1999, Transgenic Research.

[23]  Kurt Brorson,et al.  Quality by Design (QbD), Biopharmaceutical Manufacture , 2010 .

[24]  J. Richmond.  The 3Rs - Past, Present and Future , 2000 .

[25]  L. Houdebine.  [Expression of recombinant proteins in the milk of transgenic animals]. , 1993, Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine.

[26]  James L. Vesper.  Assessing and managing risks in a GMP environment , 2005 .

[27]  P. Lerouge,et al.  Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose. , 2003, Glycobiology.

[28]  M. Ayala,et al.  Expression and characterization of an anti‐(hepatitis B surface antigen) glycosylated mouse antibody in transgenic tobacco (Nicotiana tabacum) plants and its use in the immunopurification of its target antigen , 2003, Biotechnology and applied biochemistry.

[29]  C. Borroto,et al.  Hepatitis B surface antigen immunopurification using a plant-derived specific antibody produced in large scale. , 2003, Biochemical and biophysical research communications.

[30]  E. Hardy,et al.  Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. , 2000, Journal of biotechnology.

[31]  Roop K. Khar,et al.  Opportunities, challenges and benefits of using HACCP as a quality risk management tool in the pharmaceutical industry , 2009 .

[32]  F. Saudek,et al.  Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  H. Meade,et al.  Transgenic milk as a method for the production of recombinant antibodies , 1999, Journal of Immunological Methods.

[34]  P. Lerouge,et al.  N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants. , 1999, Glycobiology.

[35]  E. Winnacker,et al.  Production of transgenic mice, rabbits and pigs by microinjection , 1986 .